Sentences with phrase «effects of drugs in»

The ADF also has a SMS - based drug information service (0439 835 563) that provides information about the effects of drugs in a confidential and accessible way via mobile phone.

Not only is this a novel way to study basic biological mechanisms of these commonly targeted receptors inside the brain and individual neurons, but it's also a tool scientists can use to study specific effects of drugs in various regions of the brain.

Vaccines have shown promise in reducing the effects of drugs in research models but more needs to be learned about how to apply this therapy in the arc of addiction.

By combining the effects of both drugs in one molecule we hope that a safe and effective drug will eventually be the outcome.

Panos Zanos, a neuropharmacologist at the University of Maryland in Baltimore, says the immediate effects of the drug in the lateral habenula were interesting.

Taking the example of cocaine, researchers at Eawag, together with colleagues at Zurich University, have now shown that the uptake and distribution patterns and the effects of the drug in zebrafish differ in many ways from those in mammals.

Their new study details the effects of the drug in three patients, all of whom have been in a PVS for at least three years.

The side effects of the drug in humans have been relatively mild.

The differential effect of the drug in younger (4 - 8 months) and older (16 - 24 months) animals indicated that the stimulation of MUA was clearly associated with concomitant decrease in lipid peroxidation and lipofuscin concentration.

Not exact matches

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Merck is the latest company to weather bad news in the Alzheimer's drug race, halting a late - stage trial yesterday in an experimental amyloid - targeting candidate called verubecestat after a data monitoring committee said there was «virtually no chance of finding a positive clinical effect,» Reuters reported.

Companies like U.S. biotech giant Gilead and the U.K.'s GlaxoSmithKline (the majority stakeholder in global HIV partnership ViiV Healthcare) have developed drugs that drastically lower the chance of HIV infection — or which simply lower the number of drugs you have to take to treat it, consequently curbing the risk of toxic side effects while simplifying medical regimens.

They found that antibodies in the vaccine bound to the heroin before crossing the blood - brain barrier, thus preventing the euphoric effects of the drug.

The pink pill, which boosts dopamine and norepinephrine (both catalysts for sexual excitement) while reducing the inhibitory effects of serotonin in the brain's prefrontal cortex, is the first — and so far only — female libido drug to win FDA approval.

For decades, naloxone, a drug approved in 1971 that instantly reverses the effect of opioid overdose, languished in relative obscurity.

The density of the patient's skin and muscle slows the drug's progress, allowing it to be dispersed throughout the body in a wide spiderweb pattern, thereby hastening its effect.

«Hitler was not insane or deranged, or suffering from drug - induced delusions,» he writes, «or laboring under the effects of some chronic disease such as syphilis, or acting in an unresolved hypnotic trance: on the contrary, he was sane according to any reasonable definition of the term, and fully responsible for his actions.»

In addition to partnering with Celgene (celg) to better track negative drug side effects, IBM (ibm) is applying its cognitive computing AI technology to recommend cancer treatment in rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson HealtIn addition to partnering with Celgene (celg) to better track negative drug side effects, IBM (ibm) is applying its cognitive computing AI technology to recommend cancer treatment in rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Healtin rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Healtin the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Health.

The treaty, which is still in effect, requires all countries part of the treaty to «prevent and combat» drugs and drug addicts and to enforce punishment against the unauthorized cultivation, production or possession of opium, coca (and its derivative cocaine), marijuana and other illegal substances.

Agios Pharmaceuticals shares plunged more than 18 percent after the company discontinued development of an experimental drug for rare blood disorder due to side effects seen in a study.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The side effect was first observed earlier this month at the American Society of Hematology conference, where CEODavid Schenkein spoke with CNBC about the safety of one of the molecules in its drug, which was meant to treat pyruvate kinase deficiency, a rare, genetic anemia.

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol.

In an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effectIn an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effectin Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effects.

She said that employers» increased use of high - deductible plans, one of the side - effects of the law, has resulted in patients paying more out of pocket for the drug, and that's «where you're seeing a lot of noise around EpiPen.»

Our Government is also committed to ensuring that drug labels are written in plain language, and that the potential side effects of medication are accurately indicated.

These healthcare brands will have the effect of soothing out the inevitable fluctuations that occur on the pharmaceutical side, though right now, Glaxo's portfolio is boasting robust growth from small - scale HIV drugs Triumeq and Trivicay (which, as the CEO noted in the last annual report, sport year - over-year sales growth of 41 % and 43 %, respectively).

According to Living Goods, clients may also be reluctant to buy drugs from other private providers because of the risk of getting a counterfeit medicine.63 Living Goods sent us a study conducted at the midline of its RCT that claims that both availability of counterfeit drugs and drug prices decreased at private retailers in areas where CHPs worked.64 According to the study, about 37 % of private drug shops in the areas it studied sold fake ACT drugs, 65 and availabilty of fake ACTs was about 50 % lower among non-Living Goods sellers in the areas where Living Goods worked.66 Additional results on these potential effects will be made available when the full RCT is published.

If there is a competitive drug market, with limited advantage offered by the new drug in terms of increased effectiveness or reduced side effects, the drug will probably not win substantial market share in its product category.

ALKS 3831 is a treatment for schizophrenia that avoids the side effects of weight gain and metabolic problems that the incumbent drug has, and a phase 3 trial for it should read out in the fall of 2018.

It tells the story of «the guinea pigs»» the people most likely to be research subjects in Phase I trials, which test the safety of a drug under development by giving it to healthy subjects and examining any side effects they experience.

In contrast, positive expectations of treatment doubled the natural physiological or biochemical effect of the opioid drug among the healthy volunteers in the studIn contrast, positive expectations of treatment doubled the natural physiological or biochemical effect of the opioid drug among the healthy volunteers in the studin the study.

In many ways Betel is stricter than a lot of rehabilitation centres; no drugs are allowed, including prescription drugs, if they have a psychoactive effect.

But one important difference is that an essential part of the peyote ritual is to experience God through the mind - altering effects of the drug; that is not part of the communion service in any Christian tradition, and it is not part of any Jewish celebrations or rituals.

He said: «If more Christians... were more active in making sure they did write to people like Boots, but also any other group that is attempting to expand the use of this sort of drugs, they would have an effect as well.»

In effect he was saying that faith is an opiate, that men drug themselves with it, become sleepy, complacent and comfortable through the use of it, and that their main object in going to church is to be sprayed once more with spiritual cocaine so that they may feel less acutely the ills of life and the miseries of meIn effect he was saying that faith is an opiate, that men drug themselves with it, become sleepy, complacent and comfortable through the use of it, and that their main object in going to church is to be sprayed once more with spiritual cocaine so that they may feel less acutely the ills of life and the miseries of mein going to church is to be sprayed once more with spiritual cocaine so that they may feel less acutely the ills of life and the miseries of men.

We witness examples of such devastation in our countries such as through the use of chemical pesticides and even fertilizers, the deporting of our mineral wealth by mining transnational corporations, the exploitation of our workers, women and children and the ill - effects of drugs, arms sales and even of some types of tourism.

«god» has allegedly been measured in the brain but is indistinguishable from the effects of drugs.

The conclusion: given relatively unlimited availability, heroin users will voluntarily stabilize or reduce their dosage and some will even choose abstinence; long - addicted users can lead relatively normal, stable lives if provided legal access to their drug of choice, and with few side effects; and ordinary citizens (in Switzerland at least) will support such initiatives.

«Over time, the effect on the reward centre in the brain is similar to what makes drug addicts go back for another line of cocaine.»

We know from cases of brain damage and the effects of psychoactive drugs, that our experiences are caused by physical chemistry acting on our physical neurons in our brains.

One danger is derived from the mutually reinforcing effects of alcohol and these drugs, resulting in accidental and potentially fatal overdoses.]

When inflammation strikes, we are conditioned into reaching for a quick fix in the way of pharmaceutical or prescribed drugs such as aspirin and ibuprofen, temporary panacea's that come with their own adverse side effects and with long term use have the potential to create a host of health problems independently.

One animal study found that the anti-inflammatory effects of pumpkin seed oil worked as well as the drug indomethacin in treating arthritis.

Another study from Nigeria published in December of 2017 is titled Antioxidant and anti-inflammatory effects of virgin coconut oil supplementation abrogate acute chemotherapy oxidative nephrotoxicity induced by anticancer drug methotrexate in rats.

In 2011, Dr. Stephanie Seneff published research looking at the effects of a low - fat diet and statin drugs in relation to Alzheimer's DiseasIn 2011, Dr. Stephanie Seneff published research looking at the effects of a low - fat diet and statin drugs in relation to Alzheimer's Diseasin relation to Alzheimer's Disease.

People with kidney disease or who take warfarin should be careful with cranberry intake, as the fruit may increase oxalate excretion in urine and has the potential to increase the effects of certain pharmaceutical drugs.

Research shows the MCFAs in virgin coconut oil can boost metabolism, promote healthy weight, increase thyroid activity, strengthen the heart, protect the liver from the toxic effect of drugs and alcohol, support the healing of digestive disorders, and are vital for absorbing nutrients like Omega 3s and Vitamins E, A, D, and K.

Lowers Blood Pressure: A 2013 study published in Drug Research examined the effects of yumberry (Myrica rubra) on the cardiovascular system of rats.